May 11, 2026
Research found women undergoing breast reconstruction after mastectomy have goals extending beyond physical restoration. Newer nerve-preserving techniques aim to restore chest and nipple sensation but are still being studied.
Apr 08, 2026
Post-mastectomy pain syndrome affects 10-50% of women after breast removal surgery, causing chronic pain that can last years. The condition lacks consistent diagnosis, standardized screening, and FDA-approved treatments, leaving many patients struggling to find relief. Recent research calls for increased focus on this undertreated complication of breast cancer survival success.
Mar 03, 2026
Women with endometriosis face increased long-term risk for thyroid disorders including hypothyroidism and Graves disease, according to a 20-year retrospective study. ACOG released new clinical guidance aimed at reducing diagnostic delays through clinical diagnosis and earlier treatment initiation.
Feb 28, 2026
NRx Pharmaceuticals completed an in-person FDA Type C meeting regarding NRX-100, a preservative-free ketamine formulation for suicidal depression. The company received guidance on a path to file a New Drug Application based on existing trial data and Real World Evidence from over 65,000 patients.
Feb 26, 2026
New research from Michigan State University reveals that differences in hormone-regulated monocytes explain why women experience longer-lasting chronic pain than men, with males producing more IL-10 to shut down pain signals.
Feb 17, 2026
NRx Pharmaceuticals completed a Type C meeting with the FDA, receiving guidance to file a New Drug Application for NRX-100 based on existing trial data and real-world evidence from over 65,000 patients, with submission planned for Q2 2026.
Feb 17, 2026
NRx Pharmaceuticals completed a Type C meeting with FDA leadership and received oral guidance supporting a New Drug Application for NRX-100 (preservative-free ketamine) based on existing trial data and Real World Evidence from over 65,000 patients.